TFAP2A and lung cancer: PRMT3 orchestrates metabolic reprogramming in non–small cell lung cancer through a TFAP2A-IDO1 pathway that stimulates kynurenine synthesis to promote radioresistance and immunosuppression, highlighting this axis as a putative therapeutic target.